[go: up one dir, main page]

MX2022001417A - Formulaciones de undecanoato de testosterona proliposomal. - Google Patents

Formulaciones de undecanoato de testosterona proliposomal.

Info

Publication number
MX2022001417A
MX2022001417A MX2022001417A MX2022001417A MX2022001417A MX 2022001417 A MX2022001417 A MX 2022001417A MX 2022001417 A MX2022001417 A MX 2022001417A MX 2022001417 A MX2022001417 A MX 2022001417A MX 2022001417 A MX2022001417 A MX 2022001417A
Authority
MX
Mexico
Prior art keywords
weight
testosterone undecanoate
proliposomal
ratio
proliposomal powder
Prior art date
Application number
MX2022001417A
Other languages
English (en)
Inventor
Ramachandran Thirucote
Guru V Betageri
Natarajan Venkatesan
Teresa Hong
Nitin K Swarnakar
Veeran Gowda Kadajji
Original Assignee
Tesorx Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesorx Pharma Llc filed Critical Tesorx Pharma Llc
Publication of MX2022001417A publication Critical patent/MX2022001417A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se refiere a dispersiones de polvo proliposomal de undecanoato de testosterona (UT) y fosfolípidos, incluyendo dispersiones de UT y palmitoilfosfatidilcolina (DPPC), en donde la relación p/p es UT : DPPC en la dispersión de polvo proliposomal es de aproximadamente 1 : 2; o UT y 1,2-dimiristoil-sn glicero-3-fosfocolina (DMPC), en donde la relación peso/peso (p/p) de UT : DMPC en la dispersión de polvo proliposomal es de aproximadamente 1 : 3; o UT y una 1-miristoil-2-palmitoil-sn-glicero 3-fosfocolina (MPPC), en donde la relación peso/peso (p/p) de UT:MPPC en la dispersión de polvo proliposomal es de aproximadamente 1 : 3.
MX2022001417A 2019-08-09 2020-08-10 Formulaciones de undecanoato de testosterona proliposomal. MX2022001417A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962884919P 2019-08-09 2019-08-09
PCT/US2020/045607 WO2021030260A1 (en) 2019-08-09 2020-08-10 Proliposomal testosterone undecanoate formulations

Publications (1)

Publication Number Publication Date
MX2022001417A true MX2022001417A (es) 2022-06-08

Family

ID=74569809

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001417A MX2022001417A (es) 2019-08-09 2020-08-10 Formulaciones de undecanoato de testosterona proliposomal.

Country Status (13)

Country Link
US (1) US20220265679A1 (es)
EP (1) EP4009950A4 (es)
JP (1) JP2022544197A (es)
KR (1) KR20220054318A (es)
CN (1) CN114667133B (es)
AR (1) AR122300A1 (es)
AU (1) AU2020329775A1 (es)
BR (1) BR112022002418A2 (es)
CA (1) CA3146515A1 (es)
IL (1) IL290464A (es)
MX (1) MX2022001417A (es)
TW (1) TWI867026B (es)
WO (1) WO2021030260A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658202B2 (en) * 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
US20120135074A1 (en) * 2010-11-30 2012-05-31 Chandrashekar Giliyar High-Strength Testosterone Undecanoate Compositions
MX367123B (es) 2012-05-09 2019-08-06 Univ Western Health Sciences Formulaciones de pruebas de testosterona proliposomal.
JP6294456B2 (ja) * 2013-03-13 2018-03-14 マリンクロッド エルエルシー 修飾されたドセタキセルリポソーム製剤
EA038653B1 (ru) * 2016-01-07 2021-09-29 Вестерн Юниверсити Оф Хелт Сайенсиз Составы для лечения рака мочевого пузыря
CN108601736A (zh) * 2016-01-08 2018-09-28 健康科学西部大学 前体脂质体十一酸睾酮制剂
CR20190274A (es) * 2016-11-11 2019-07-29 Univ Western Health Sciences Formulaciones liposomales para interacciones farmacológicas contra carcinoma del tracto superior

Also Published As

Publication number Publication date
JP2022544197A (ja) 2022-10-17
AR122300A1 (es) 2022-08-31
AU2020329775A1 (en) 2022-02-24
CA3146515A1 (en) 2021-02-18
IL290464A (en) 2022-04-01
EP4009950A4 (en) 2023-07-05
US20220265679A1 (en) 2022-08-25
TWI867026B (zh) 2024-12-21
EP4009950A1 (en) 2022-06-15
CN114667133A (zh) 2022-06-24
KR20220054318A (ko) 2022-05-02
BR112022002418A2 (pt) 2022-06-14
CN114667133B (zh) 2025-01-14
WO2021030260A1 (en) 2021-02-18
TW202216162A (zh) 2022-05-01

Similar Documents

Publication Publication Date Title
MX2024013597A (es) Composiciones de nanoparticulas lipidicas para suministro de agentes biologicamente activos
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MX2020001187A (es) Composiciones y métodos para la administración de virus adenoasociados.
MX2023009527A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
WO2019036008A8 (en) Lipids for use in lipid nanoparticle formulations
MX2024008101A (es) Formulaciones de nanoparticulas lipidicas para componentes de cas/crispr.
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
CL2018003604A1 (es) Composiciones farmacéuticas para terapia combinada (divisional solicitud 201701983)
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
PE20130045A1 (es) FORMULACIONES INTRAVENOSAS DE COENZIMA Q10 (CoQ10) Y METODOS DE USO DE LAS MISMAS
WO2019186284A3 (en) Defined dose cannabis puck
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
MX2025000643A (es) Nanomateriales que comprenden trioles
MX2023011701A (es) Composicion farmaceutica para liberacion controlada de treprostinil.
MX2021011430A (es) Composicion bucal semisolida de fases multiples que comprende particulas hidrofilas del agente activo.
PE20200794A1 (es) Composicion para su uso en la prevencion y el tratamiento de patologias del aparato cardiovascular
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
MX2025006782A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina-1 (irak4) y usos de los mismos
PH12019500137A1 (en) Vaginal composition comprising a combination of estrogen and vitamin d
MX2018000021A (es) Composiciones multifasicas.
MX2022001417A (es) Formulaciones de undecanoato de testosterona proliposomal.
BR112014027653A2 (pt) formulações para a liberação dos ingredientes ativos
WO2020260956A3 (en) Self-emulsifying cannabidiol formulations
WO2020165057A8 (en) Compositions containing bacillaene producing bacteria or preparations thereof
BR112018007399A2 (pt) composição, método de tratamento, kit de partes e forma de dosagem